Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy

European Journal of Cancer Prevention

Volumn 25, Issue 4, 2016, Pages 312-320

  Gee, Jason R ^a   Saltzstein, Daniel R ^b   Messing, Edward ^c   Kim, Kyung Mann ^a   Kolesar, Jill ^a   Huang, Wei ^a   Havighurst, Thomas C ^a   Harris, Linda ^a   Wollmer, Barbara W ^a   Jarrard, David ^a   House, Margaret ^d   Parnes, Howard ^d   Bailey, Howard H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Urology San Antonio Research   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Diindolymethane; Prostate cancer

Indexed keywords

16 HYDROXYESTRONE; 2 HYDROXYESTRONE; 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CASPASE 3; CYTOCHROME P450; KI 67 ANTIGEN; MESSENGER RNA; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; TUMOR MARKER;

ADULT; ANOREXIA; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; FATIGUE; FLATULENCE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; TISSUE LEVEL; ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ANTICARCINOGENIC AGENTS; BIOMARKERS, TUMOR; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84973523332     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000189     Document Type: Article

References (23)

1. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202.
2. Cohen JH, Kristal AR, Stanford JL (2000). Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92:61-68.
3. Crowell JA, Page JG, Levine BS, Tomlinson MJ, Hebert CD (2006). Indole-3-carbinol, but not its major digestive product 3, 3'-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochrome P450. Toxicol Appl Pharmacol 211:115-123.
4. Falk RT, Rossi SC, Fears TR, Sepkovic DW, Migella A, Adlercreutz H, et al. (2000). A new ELISA kit for measuring urinary 2-hydroxyestrone, 16-alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev 9:81-87.
5. Gross-Steinmeyer K, Stapleton PL, Liu F, Tracy JH, Bammler TK, Quigley SD, et al. (2004). Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes. Xenobiotica 34:619-632.
6. Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, et al. (2010). A phase I dose-escalation study of oral BR-DIM (BioResponse 3, 3'-diindo-lylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res 2:402-411.
7. Jain MG, Hislop GT, Howe GR, Ghadirian P (1999). Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer 34:173-184.
8. Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, et al. (2009). Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol 64:79-86.
9. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, et al. (2000). Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 9:795-804.
10. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF (2003). Plant-derived 3, 3'-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 278:21136-21145.
11. Lieberman R (2001). Prostate cancer chemoprevention: strategies for designing efficient clinical trials. Urology 57 (4 Suppl 1):224-229.
12. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39-51.
13. Nachshon-Kedmi M, Fares FA, Yannai S (2004a). Therapeutic activity of 3, 3'-diindolylmethane on prostate cancer in an in vivo model. Prostate 61:153-160.
14. Nachshon-Kedmi M, Yannai S, Fares FA (2004b). Induction of apoptosis in human prostate cancer cell line, PC3, by 3, 3'-diindolylmethane through the mito-chondrial pathway. Br J Cancer 91:1358-1363.
15. Nelson WG, Wilding G (2001). Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology 57 (4 Suppl 1):56-63.
16. Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, et al. (2012). Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential che-mopreventive activities. Cancer Prev Res (Phila) 5:290-298.
17. Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, et al. (2011). 3, 3'-Diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid 21:299-304.
18. Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, et al. (2005). A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14:1953-1960.
19. Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A (2008). Single-dose pharmacokinetics and tolerability of absorption-enhanced 3, 3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 17:2619-2624.
20. Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL (2004). Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164:831-840.
21. Siegel R, Naishadham D, Jemal A (2012). Cancer Statistics, 2012. CA Cancer J Clin 62:10-29.
22. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224.
23. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W (2009). Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol 17:23-30.